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These PRP–alginate–silica compositions can be used as injectable
carriers for viable mesenchymal stem cells.Platelet-rich plasma (PRP) is an autologous source of growth factors
(GF) derived from blood plasma. It holds great promise in various
clinical applications such as periodontal and maxillofacial surgery,
spinal fusion, bone augmentation and treatment of skin and soft
tissue ulcers.1 In a study comprising 88 patients Marx et al. have
shown that bone autogenous bone grafts with PRP displayed
a significantly higher bone trabecular density and maturity in the
reconstruction of maxillofacial defects.2 In another study, Margolis
et al. showed on a large set of patients that PRP treatment for dia-
betic foot ulcers was more effective than the standard one.3 However,
other studies have shown that PRP does not accelerate or improve
the healing process.4,5 These contradictory results have been attrib-
uted to the low control of the spatial and temporal delivery of PRP6
and the variability in the quantity of growth factors between different
PRP preparations.7
In typical preparations, the release kinetics of pure PRP is very fast
with more than 95% released in the first hour.7 This can be slowed
down by combining PRP with biomaterials (e.g. ceramic,8 polymer
scaffolds9 or gelatin gels10) which is found to increase PRP
efficiency. In vitro, Lu et al. have shown using PRP–alginate beads
that by controlling the spatial and temporal release of PRP growth
factors, the osteogenic differentiation of stem cells could be
promoted.6
Mesenchymal stem cells (MSCs) are a cell type of choice for tissue
engineering applications. As for PRP, MSCs are of autologous origin
and possess the ability to differentiate to different cell types under
appropriate stimuli.11 They can be used in combination with a carrier
(e.g. scaffold, hydrogel, etc.) for a variety of applications. ForaAO Research Institute Davos, Clavadelerstrasse 8, 7270 Davos,
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This journal is ª The Royal Society of Chemistry 2011example several studies have investigated the combination of PRP
with mesenchymal stem cells (MSCs), showing positive results in
various in vivo models.12,13 However, there are other experimental
results that showed no significant improvement in the presence of
PRP,14 emphasising the need for a better control of PRP release.
Ideally, a PRP delivery system should be injectable, provide fine-
tuning of PRP release and allow for cell encapsulation. Current two-
component systems composed of alginate and PRP allow for
injectability and cell encapsulation,6,12 but the ability to finely tune
PRP protein and growth factors release is limited.
In our study, we introduced a third component, silica nano-
particles, during alginate–PRP gel synthesis to generate novel parti-
cles with the end goal being to modulate the release of TGF-b1 from
the beads. It is known that the size or curvature of silica nano-
particles influences protein adsorption and conformation15,16 such
that a synthesis method for the particles was adopted whereby silica
particles of 200–250 nm could be rapidly produced under mild
conditions (pH 7) compatible with alginates, PRP and other
components such as cells.17 The synthesis was performed by addition
of pentaethylenehexamine (PEHA), itself a mimic of molecules found
in many silicifying organisms.18,19 PEHA was chosen as variation of
the reaction conditions including concentration and modest changes
in pH could lead to a wide variety of particle sizes being formed. The
other main component, alginate is a well-known injectable carrier,
often used for cell and growth factor encapsulation, due to its mild
gelation and controlled release properties, respectively.20 It is a linear
unbranched polysaccharide containing varying amounts of 1,40-
linked b-D-mannuronic acid and a-L-guluronic acid that can be
crosslinked by divalent ions (e.g. Ca2+, Mg2+). This gelation is suffi-
ciently mild to preserve cells and growth factors viability.20–22 The
kinetics of diffusion of molecules from the alginate network can be
modified by changing the sizes of its pores via changes to the ionic
strength used during synthesis.23 The combination of silica nano-
particles with alginate and PRP would offer thereby a powerful tool
to tune the release of PRP growth factors.
The aim of this study was to validate for the first time the use of
a novel PRP–alginate–silica composite gel for combined controllable
PRP release and cell-based therapy. Following characterisation of the
materials formed, the effect of the presence of silica nanoparticles
within the new composite materials on the release of total proteins
and the transforming growth factor b1 (TGF-b1, one of the most
abundant growth factors in PRP) was investigated. Finally,
a successful protocol for MSCs encapsulation was established and theJ. Mater. Chem.
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View Onlineeffect of silica condensation in an alginate–PRP hydrogel on the
viability of MSCs over three days was studied.
PRP–alginate beads with or without silica were prepared. A
detailed description of the experimental procedure is available as
ESI†. Briefly, sodium alginate was dissolved in Iscoves Modified
Dulbecco’s medium (IMDM), followed by the addition of appro-
priate amounts of sodium metasilicate nonahydrate
(Na2SiO3$9H2O). This solution was then mixed with an equal
volume of a PRP/thrombin solution. Macro-beads with an average
diameter of 4 mm were prepared by adding the mixture dropwise into
a CaCl2 solution (pH 7) containing PEHA by use of an auto-injector.
The presence of the amine promoted the rapid condensation and
aggregation of silica.17,18 Gel beads were formed immediately and left
maturating for 10 min in the CaCl2 solution at room temperature.
The novel gel beads were lyophilised before being characterised
by infrared spectroscopy (Fig. 1A) and electron microscopy
(Fig. 1B and C). Compared to the reactants and the PRP–alginate
bead mid-IR profiles, the PRP–alginate–silica bead mid-IR spec-
trum showed additional vibrational bands at 1000 cm1, 950 cm1
and 450 cm1, attributable to Si–O stretching and bending vibra-
tions in silica, indicating the polycondensation of silicate (or
silicon species) within the beads (Fig. 1A). This was confirmed by
the use of a colorimetric assay for silicon,24 with the total silicon
content in the PRP–alginate–silica beads representing 22% of the
initial silicon content added.
Fractured and calcined (700 C) PRP–alginate–silica beads
examined by SEM showed aggregated silica particles of size around
50–200 nm suggesting PEHA catalyzed condensation of silicon
species within the PRP–alginate beads (Fig. 1B and C), similarly to
previous studies on silica condensation in the presence of PEHA and
polysaccharide/protein compositions.18,25,26Fig. 1 Mid FT–IR spectra of lyophilized PRP–alginate and PRP–algi-
nate–silica beads (A). SEM images of lyophilized PRP–alginate–silica
bead 100 mM sodium metasilicate (B) and calcined PRP–alginate–silica
bead 100 mM sodium metasilicate concentration with a higher magnifi-
cation image in the inset (C).
J. Mater. Chem.To prove the first evidence that silica nano-particles modify protein
release from PRP–alginate gels, a high concentration of silicate
(100 mM) was initially added to the reaction medium and total
protein release from the beads and appropriate controls without silica
was monitored over 4 days (Fig. 2). For the PRP–alginate beads (no
silica), there was an initial fast release (95% of protein released within
the first 2 h), followed by a plateau with no further material being
released over the remainder of the experiment. For the PRP–algi-
nate–silica beads, the amount of protein initially released was lower
(approximately 80% after 2 h) and slow protein release continued
over the next 78 h. Although the protein encapsulation efficiencies
have not been specifically addressed, a previous study of protein
release from alginate–PRP beads showed that protein loading in such
systems is close to 100%.6 Interactions between polycondensed
silica, a protein (gelatin) and alginate25 are reported to be low between
alginate and silica, and strong between the protein studied and silica
and we anticipate the yield from the alginate–silica–protein beads
described in this contribution to be as high as from alginate–protein
beads.
Once evidence for the ability of the gel beads containing silica
nano-particles to modify the release profile of ‘total protein’ was
obtained, the next step was to investigate the effect of silica nano-
particles on PRP growth factors release and viability of encapsulated
cells in the alginate–PRP–silica hydrogel. Therefore, the maximum
silicate concentration explored was reduced to 50 mM to match
physiological osmolarity (300–330 mOsm).
To assess the ability of silica nano-particles to moderate the release
of growth factors, the release of TGF-b1 from PRP–alginate beads
prepared with different concentrations of sodium metasilicate (0, 5,
25 and 50 mM) was measured (ESI†). The variation of TGF-b1
release by the PRP–alginate beads with different concentrations of
sodium metasilicate was difficult to interpret due to the large standard
deviation values associated with material inhomogeneities (e.g.
aggregates) that are commonly found in this kind of preparation.
Nonetheless, all the sodium metasilicate containing beads showed
a slower and significantly higher release of TGF-b1 at 48 h than the
PRP–alginate system alone.
Finally, the potential of this novel injectable composite system for
cell encapsulation was tested. Human MSCs (hMSCs) were isolatedFig. 2 Plots of total protein release from the PRP–alginate beads (B)
and PRP–alginate–silica beads prepared with 100 mM silicon concen-
tration (,) as a function of time in PBS solution at 37 C; average and
standard deviation are reported.
This journal is ª The Royal Society of Chemistry 2011
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View Onlineaccording to a reported procedure.27 hMSCs were suspended in
alginate, alginate–silica, PRP–alginate with thrombin, PRP–alginate–
silica with thrombin (cell density of 3 106 cells.ml1). Three different
concentrations of sodium metasilicate (5, 25 and 50 mM) were tested
and the PRP–alginate volume ratio was set as 0.9. The pH and the
ionic strength of the solutions were adjusted respectively to 7.4 and
330 mOsm or as close as possible in the case of the 50 mM silicate
concentration. Once the pH and ionic strength had been adjusted for
the different solutions, hMSCs could be encapsulated and were then
cultured for 3 days. After dissolution of the beads,28 the proportion of
viable cells in the various silica-containing beads compared to the
initial number of cells seeded was measured by the trypan blue
exclusion assay (Fig. 3).
After one day of culture, the addition of silicate significantly
increased the proportion of viable cells, both in alginate and PRP–
alginate samples as compared to the controls (alginate and PRP–
alginate without silicate) suggesting that the presence of the silicate in
the preparation reduces any negative effect of the alginate gel
formation on cell viability. The highest proportion of viable cells was
achieved at a low silicate concentration (5 mM) which is probably due
to the ability of low molecular weight silica species being most
effective in disrupting the alginate network. With increasing amounts
of silicate in the preparation (5 to 50 mM), the proportion of viable
hMSCs in alginate–silica–PRP/no PRP (Fig. 3A and B) after 1 day of
culture decreased in a linear fashion (Fig. 3B has R2 ¼ 0.999). It is
likely that reactive silicon species are trapped in the alginate gel that
rapidly forms following Ca2+ diffusion with silica particles continuing
to form over time within the gel structure. The resulting physical
changes in the gel matrix could possibly damage the immobilized cells
in the hydrogel which could explain the reduced numbers of viable
cells at higher silicate concentrations.
After three days of culture, the proportion of viable hMSC in the
PRP–alginate–silica samples was high (0.91–0.93), independent of the
silicate concentration. This is possibly due to the sustained release of
growth factors (Fig. 2) in the presence of silicate compared to algi-
nate–PRP samples without silicate (Fig. 3B) as hMSCs express the
membrane receptors to the growth factors present in PRP and PRP is
known to stimulate hMSCs proliferation.2,29 This effect was maximal
with the highest silicate concentration. It is known that gelatin–algi-
nate interactions are weak while gelatin–silica are strong25 and that
alginate modulates the yield and release kinetics of the differentFig. 3 Plots of the proportion of viable hMSCs relative to the initial
viability of the seeded hMSC at 1 and 3 days of culture in alginate–silica
beads with 0, 5, 25 and 50 mM silicate concentration (A) and in PRP–
alginate–silica beads with 0, 5, 25 and 50 mM silicate concentration (B).
(Data: average and standard deviation, lines p < 0.05 silicate concen-
trations, *p < 0.05 day 1 versus day 3.)
This journal is ª The Royal Society of Chemistry 2011growth factors contained in the PRP.6 Therefore, we would expect
that the yields and kinetics of the different proteins to be affected by
the presence of silica in the PRP–alginate composition.
Without silica (see Fig. 3A), the proportion of viable hMSCs in
alginate beads after 3 days of culture was lower (0.63). The addition
of PRP to alginate was beneficial at 24 h, although, after 3 days of
culture, the proportion of viable cells in both alginate and PRP–
alginate beads was still relatively low (0.68) suggesting that the
presence of PRP could only partially overcome the hMSCs initial
adverse reaction to the alginate environment (lack of binding sites).
The weak effect of PRP addition of later time points may be
explained by rapid protein release (4 h) in the absence of silica
added to the preparation (Fig. 2). The exact mechanism of interaction
between the composite materials and cells has not yet been elucidated.
However, our hypothesis is that the small molecular weight oligomers
and higher molecular weight nano-sized silica particles influence the
physical and chemical characteristics of the polymer network as well
as making possible the retention of proteins within the beads enabling
an extended effect of PRP on encapsulated hMSCs.
In summary, we have reported a novel method for combined
controlled PRP release and mesenchymal stem cell encapsulation. In
recent years, it has been shown that combined growth factor delivery
is more effective than delivery of a single factor30 as growth factors
each have a different role to play in a time dependent manner.
Although delivery systems for sequential release of recombinant
growth factors have already been proposed30 using composites where
different components are separately loaded with individual growth
factors they are not suitable for an autologous source of growth
factors such as PRP as it is itself a mixture of proteins and growth
factors. The synthetic approach described in this contribution
combining silica with alginate could offer for the first time the
opportunity to tune PRP growth factor release. Furthermore, this
composite system is injectable and preserves the viability of hMSCs,
thereby opening the way for combined tissue engineering and drug
delivery applications.Notes and references
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